Ashley D. Chadha, Isaac P. Thomsen, Natalia Jimenez-Truque, Nicole R

Slides:



Advertisements
Similar presentations
Long-term non-invasive ventilation in cystic fibrosis — Experience over two decades William G. Flight, Jonathan Shaw, Susan Johnson, A. Kevin Webb, Andrew.
Advertisements

J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Safety and efficacy of Creon® Micro in children with exocrine pancreatic insufficiency due to cystic fibrosis  Nataliya Y. Kashirskaya, Nikolay I. Kapranov,
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Serum matrix metalloproteinases in adult CF patients: Relation to pulmonary exacerbation  Martin Roderfeld, Timo Rath, Richard Schulz, Werner Seeger,
Treatment compliance in children and adults with Cystic Fibrosis
Reduced levels of active GLP-1 in patients with cystic fibrosis with and without diabetes mellitus  Magnus Hillman, Leif Eriksson, Lena Mared, Karin Helgesson,
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
Is infection with hypermutable Pseudomonas aeruginosa clinically significant?  Adi Auerbach, Eitan Kerem, Marc Victor Assous, Elie Picard, Maskit Bar-Meir 
Sweat conductivity: An accurate diagnostic test for cystic fibrosis?
William G. Flight, Jonathan Shaw, Susan Johnson, A
Jodi E. Gustave, Joseph A. Jurcisek, Karen S. McCoy, Steven D
How does heart rate recovery after sub-maximal exercise correlate with maximal exercise testing in children with CF?  Sarah P. Cohen, David M. Orenstein 
Avani C. Modi, Crystal S. Lim, Nami Yu, David Geller, Mary H
Development of a quantitative immunofluorescence assay for detection of Stenotrophomonas maltophilia antibodies in patients with cystic fibrosis  P. Gonçalves.
A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children.
J.H.K. Hull, W. Tucker, A.G. Hatrick, R.K. Knight, T.B.L. Ho 
Megan R. Nelson, Craig R. Adamski, Audrey Tluczek 
Urinary incontinence in 9���16��year olds with cystic fibrosis compared to other respiratory conditions and a normal group  W.J. Browne, C.J. Wood, M.
Nadav Traeger, Qiuhu Shi, Allen J. Dozor  Journal of Cystic Fibrosis 
Measures of body habitus are associated with lung function in adults with cystic fibrosis: A population-based study  Doug L. Forrester, Alan J. Knox,
Design and powering of cystic fibrosis clinical trials using pulmonary exacerbation as an efficacy endpoint  D.R. VanDevanter, A. Yegin, W.J. Morgan,
Microbiological yield from induced sputum compared to oropharyngeal swab in young children with cystic fibrosis  Marco Zampoli, Komala Pillay, Henri Carrara,
Laura Viviani, Baroukh M. Assael, Eitan Kerem 
Eradication of chronic methicillin-resistant Staphylococcus aureus infection in cystic fibrosis patients. An observational prospective cohort study of.
A longitudinal analysis of chronic MRSA and Pseudomonas aeruginosa co-infection in cystic fibrosis: A single-center study  Maret L. Maliniak, Arlene A.
Cirrhosis and other liver disease in cystic fibrosis
The ease of breathing test tracks clinical changes in cystic fibrosis
Increased serum concentration of G-CSF in cystic fibrosis patients with chronic Pseudomonas aeruginosa pneumonia  P.Ø. Jensen, C. Moser, A. Kharazmi,
Amanda L. Brennan, Khin M. Gyi, David M
Pulmonary exacerbations in CF patients with early lung disease
The applicability of urinary creatinine as a method of specimen normalization in the cystic fibrosis population  Brandie D. Wagner, Frank J. Accurso,
Clinical outcomes in cystic fibrosis patients with Trichosporon respiratory infection  Charles R. Esther, Rongpong Plongla, Alan Kerr, Feng-Chang Lin,
Controlled clinical trials in cystic fibrosis — are we doing better?
D. Stevens, P.J. Oades, N. Armstrong, C.A. Williams 
Claire J. Tipping, Rebecca L. Scholes, Narelle S. Cox 
Cystic fibrosis mortality trend in Italy from 1970 to 2011
Comparison of real time diagnostic chemistries to detect Pseudomonas aeruginosa in respiratory samples from cystic fibrosis patients  J.L. Fothergill,
A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis  Barry J Plant, Damian G Downey, Joe.
An evaluation strategy for potential QTc prolongation with chronic azithromycin therapy in cystic fibrosis  Patrick John Lenehan, Craig M. Schramm, Melanie.
A.H. Gifford  Journal of Cystic Fibrosis 
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009  Yolanda P. Lillquist,
Physiologic endpoints for clinical studies for cystic fibrosis
Colon Cancer in Cystic Fibrosis patients: Is this a growing problem?
Higher Interleukin-7 serum concentrations in patients with cystic fibrosis correlate with impaired lung function  Julia Seyfarth, Sutharsan Sivagurunathan,
Stenotrophomonas maltophilia in cystic fibrosis: Improved detection by the use of selective agar and evaluation of antimicrobial resistance  P. Goncalves-Vidigal,
Narelle S. Cox, Jennifer Follett, Karen O. McKay 
Inflammatory and immunological biomarkers are not related to survival in adults with Cystic Fibrosis  K.L. Moffitt, S.L. Martin, A.M. Jones, A.K. Webb,
Theresa A. Laguna, Cynthia B. Williams, Kyle R
Alina A. Ionescu, Lisette S. Nixon, Dennis J. Shale 
Respiratory pathogens mediate the association between lung function and temperature in cystic fibrosis  Joseph M. Collaco, Karen S. Raraigh, Lawrence.
Trends in pathogens colonising the respiratory tract of adult patients with cystic fibrosis, 1985–2005  F.A. Millar, N.J. Simmonds, M.E. Hodson  Journal.
Successful treatment of cepacia syndrome with a combination of intravenous cyclosporin, antibiotics and oral corticosteroids  Francis J. Gilchrist, A.
K. Budding, E. A. van de Graaf, T. Hoefnagel, J. M. Kwakkel-van Erp, D
V. Thompson, N. Mayer-Hamblett, M. Kloster, D. Bilton, P.A. Flume 
Serology as a diagnostic tool for predicting initialPseudomonas aeruginosa acquisition in childrenwith cystic fibrosis  Cori Daines, Donald VanDeVanter,
J.E. Spahr, R.B. Love, M. Francois, K. Radford, K.C. Meyer 
Daniel J. Smith, Gregory J. Anderson, Scott C. Bell, David W. Reid 
Voriconazole therapy in children with cystic fibrosis
The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation  C. Etherington,
Gut dysbiosis in cystic fibrosis
‘Peeling paint’ dermatitis as a presenting sign of cystic fibrosis
Comparison of rhinovirus antibody titers in children with asthma exacerbations and species-specific rhinovirus infection  Jua Iwasaki, BSc (Hons), Wendy-Anne.
Cheryl Cameron, Mark W. Lodes, William M. Gershan 
Khin M. Gyi, Margaret E. Hodson, Magdi Y. Yacoub 
David Adeboyeku, Sandra Scott, Margaret E. Hodson 
Elisabeth P. Dellon, Margaret W. Leigh, James R. Yankaskas, Terry L
Changing thresholds and incidence of antibiotic treatment of cystic fibrosis pulmonary exacerbations, 1995–2005  Donald R. VanDevanter, Eric P. Elkin,
Anne K. Swisher, Kathryn Moffett, Linda Baer 
R. D. Gray, M. Imrie, A. C. Boyd, D. Porteous, J. A. Innes, A. P
Presentation transcript:

Host response to Staphylococcus aureus cytotoxins in children with cystic fibrosis  Ashley D. Chadha, Isaac P. Thomsen, Natalia Jimenez-Truque, Nicole R. Soper, Lauren S. Jones, Andrew G. Sokolow, Victor J. Torres, C. Buddy Creech  Journal of Cystic Fibrosis  Volume 15, Issue 5, Pages 597-604 (September 2016) DOI: 10.1016/j.jcf.2015.12.023 Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 1 Study overview. Children within the target age range with approached in the Vanderbilt Cystic Fibrosis Clinic and invited to participate in the study. Subjects were recruited until 50 subjects were enrolled, a sample size calculated based on our previous studies of serologic responses to target antigens. Journal of Cystic Fibrosis 2016 15, 597-604DOI: (10.1016/j.jcf.2015.12.023) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 2 Geometric mean IgG titers in serum from children with cystic fibrosis. For those subjects that experienced pulmonary exacerbation during the study period, titers are measured during exacerbation and at follow-up (1–3months). For LukA, alpha toxin and LukS-PV, geometric mean titers (GMT) were significantly higher if S. aureus was detected at the time of exacerbation (p<0.01 for each comparison; Mann–Whitney U test). For LukA only, GMTs were significantly higher at exacerbation follow-up compared to titers during the exacerbation (p<0.05, Wilcoxon signed-rank test). Journal of Cystic Fibrosis 2016 15, 597-604DOI: (10.1016/j.jcf.2015.12.023) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 3 Predictive capacity of LukAB serology in relation to detection of S. aureus during pulmonary exacerbation. Number of samples for each given titer range are displayed. A line is arbitrarily drawn at a titer of 1:160 to demonstrate a potential cut-off value for possible predictive capacity of a positive titer. In this dataset, the presence of a positive S. aureus culture during a pulmonary exacerbation resulted in a 34-fold increase in odds of having a LukA titer ≥1:160. Journal of Cystic Fibrosis 2016 15, 597-604DOI: (10.1016/j.jcf.2015.12.023) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions

Fig. 4 Neutralization of LukAB-mediated PMN-HL60 cytotoxicity in the presence of children with cystic fibrosis or healthy controls. Sera obtained during exacerbations when S. aureus was isolated were significantly more potent than those in which S. aureus was not isolated (P<0.01, independent t-test) or healthy control sera (P<0.001, independent t-test) as measured by geometric mean neutralization titer. Neutralizing capacity did not significantly differ during and post-exacerbation. Journal of Cystic Fibrosis 2016 15, 597-604DOI: (10.1016/j.jcf.2015.12.023) Copyright © 2016 European Cystic Fibrosis Society. Terms and Conditions